supported by the Natural Science Foundation of Zhejiang Province(LY19H160009 and LY20H120007);the National Natural Science Foundation of China(82130053,81971871,31970845 and 81901571);the Joint Preresearch Fund for Clinical Scientific Research of Hangzhou First People’s Hospital Affiliated to Zhejiang University(YYJJ2019Z07);the Major Project of Hangzhou Health Science and Technology Plan(Z20200134).
Although chimeric antigen receptor-modified(CAR)T cell therapy has been successfully applied in the treatment of acute B lymphocytic leukemia,its effect on Burkitt lymphoma(BL)and chronic B lymphocytic leukemia(B-CLL)...